Global Leading Market Research Publisher QYResearch announces the release of its latest report “RNA Ligase – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global RNA Ligase market, including market size, share, demand, industry development status, and forecasts for the next few years.
For molecular biologists, genomics researchers, and synthetic biology engineers, joining RNA fragments or circularizing RNA molecules is essential for RNA repair, small RNA sequencing library construction, RNA labeling, and probe preparation. The RNA ligase addresses this through ATP-dependent phosphodiester bond formation: enzymes catalyzing the joining of two RNA molecules or intra-strand circularization, with T4 RNA ligase 1 (single-stranded RNA or RNA-DNA) and T4 RNA ligase 2 (double-stranded RNA ends) as the primary tools. According to QYResearch’s updated model, the global market for RNA Ligase was estimated to be worth US$ 83.77 million in 2025 and is projected to reach US$ 112 million, growing at a CAGR of 4.3% from 2026 to 2032. RNA ligases are enzymes that catalyze the formation of phosphodiester bonds between two RNA molecules or within a single RNA strand, thereby joining or circularizing RNA fragments. They play a vital role in molecular biology experiments such as RNA repair, RNA interference, small RNA sequencing library construction, RNA labeling, and molecular probe preparation. Based on their source and function, RNA ligases can be divided into T4 RNA ligase 1 (which catalyzes single-stranded RNA or RNA-DNA ligation) and T4 RNA ligase 2 (which prefers to join double-stranded RNA ends). These enzymes typically rely on ATP as an energy source. These enzymes are widely used in fields such as high-throughput sequencing, noncoding RNA research, and synthetic biology.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6098343/rna-ligase
1. Technical Architecture: Ligase Types and Substrate Specificity
RNA ligases are segmented by substrate preference, determining application suitability:
| Ligase Type | Substrate Specificity | ATP Requirement | Typical Reaction Time | Applications | Market Share (Revenue) |
|---|---|---|---|---|---|
| T4 RNA Ligase 1 | Single-stranded RNA, RNA-DNA hybrids | Yes (ATP) | 30-60 min | RNA labeling, 5′-end labeling, RNA circularization | 45% |
| T4 RNA Ligase 2 | Double-stranded RNA ends (nicked or blunt) | Yes (ATP) | 15-30 min | Small RNA-seq library prep, miRNA cloning | 50% |
| Other (Rnl2, Trl1) | Specialized (tRNA repair, viral RNA ligation) | Yes (ATP or GTP) | Varies | Research applications | 5% |
Key technical challenge – ligation efficiency with small RNA fragments (<20 nt): Traditional RNA ligases have low efficiency for microRNA (miRNA) and small interfering RNA (siRNA) fragments. Over the past six months, several advancements have emerged:
- New England Biolabs (February 2026) introduced a thermostable RNA ligase (from Thermus thermophilus) with 10x higher efficiency for small RNA (15-25 nt) ligation, enabling complete conversion of miRNA to sequencing libraries (vs. 30-50% with T4 RNA ligase).
- Yeasen (March 2026) commercialized a T4 RNA ligase 2 mutant (K227Q) with reduced adenylation activity, minimizing adapter-dimer formation in small RNA-seq libraries, improving data quality and reducing wasted reads.
- Thermo Fisher Scientific (January 2026) launched an RNA ligase with proprietary buffer formulation (PEG-enhanced), reducing reaction time from 1 hour to 15 minutes for high-throughput automation workflows.
Industry insight – unit economics: RNA ligases are sold as research-grade enzymes ($200-500 for 1,000-10,000 units) and GMP-grade for diagnostic kit manufacturing ($500-2,000). The market is reagent-driven (consumables) with high gross margins (60-80%). Next-generation sequencing (NGS) library preparation is the largest volume application, consuming 50-100 reactions per sequencing run.
2. Market Segmentation: Ligase Type and Application
The RNA Ligase market is segmented as below:
Key Players: New England Biolabs (US), Yeasen (China), Thermo Fisher Scientific (US), Qiagen (Germany), Yinjia Biological (China), Beijing Generaybiotech (China), Codexis (US), Aji Bio-Pharma (Japan), KACTUS (China), Hzymes Biotechnology (China), Enzynomics (South Korea), Promega Corporation (US), Almac (UK)
Segment by Ligase Type:
- T4 RNA Ligase 2 – Largest segment (50% of 2025 revenue). Double-stranded RNA ligation, small RNA-seq library prep.
- T4 RNA Ligase 1 – 45% of revenue. Single-stranded RNA labeling, circularization.
- Other – 5% of revenue. Specialized applications.
Segment by Application:
- High-throughput Sequencing – Largest and fastest-growing segment (45% of revenue, 6% CAGR). Small RNA-seq (miRNA, piRNA), single-cell RNA-seq (3′ end library prep), CLIP-seq (RNA-protein interaction).
- Molecular Biology – 25% of revenue. RNA ligation for cloning, RNA repair, RNA interference (siRNA ligation), molecular probes.
- RNA Repair and Synthetic Biology – 15% of revenue. tRNA repair (anticodon loop), ribozyme engineering, synthetic RNA circuits.
- Medicine and Drug Discovery – 10% of revenue. RNA therapeutics (circular RNA synthesis), diagnostic assay development.
- Other – Agricultural biotech, environmental monitoring (5% of revenue).
Typical user case – small RNA-seq library preparation: A genomics core facility processes 500 small RNA-seq samples per month (miRNA, piRNA). Using T4 RNA ligase 2 (NEB, $300/kit, 50 reactions), each reaction requires 30 min incubation. Monthly cost: $3,000 (enzymes). The facility upgraded to thermostable RNA ligase (Yeasen, $400/kit) with 10x efficiency, reducing failed library rate from 15% to 5%, saving $1,500/month in sequencing costs.
Exclusive observation – “circular RNA” (circRNA) therapeutic driver: Circular RNA therapeutics (stable, non-immunogenic RNA molecules) require RNA ligase for circularization during synthesis. Several biotech companies (Orna Therapeutics, Laronde) are developing circRNA-based drugs; each manufacturing batch consumes gram quantities of RNA ligase. This emerging application could double RNA ligase market size by 2028.
3. Regional Dynamics and Genomics Research
| Region | Market Share (2025) | Key Drivers |
|---|---|---|
| North America | 45% | Largest genomics research base (US), NGS market leaders (Illumina, Thermo Fisher), biotech hubs |
| Asia-Pacific | 30% | Fastest-growing (6% CAGR), China (BGI, sequencing services), Japan, South Korea (NGS adoption) |
| Europe | 20% | Genomics research (UK, Germany, Switzerland), synthetic biology (UK, France) |
| RoW | 5% | Emerging research (Australia, Brazil, Israel) |
Exclusive observation – “single-cell RNA-seq” driver: Single-cell RNA-seq (10x Genomics, Parse Biosciences) uses RNA ligation for 3′ end library construction. As single-cell applications grow (oncology, immunology, neuroscience), RNA ligase consumption increases. Each single-cell library uses 10-20 reactions, with 1,000+ cells per experiment. Single-cell RNA-seq market growing at 15% CAGR, driving RNA ligase demand.
4. Competitive Landscape and Outlook
| Tier | Supplier | Key Strengths | Focus |
|---|---|---|---|
| 1 | Global molecular biology leaders | NEB (US), Thermo Fisher (US), Promega (US), Qiagen (Germany) | Brand trust, complete workflow (RNA-seq kits), premium pricing |
| 1 | Asian suppliers | Yeasen (China), Enzynomics (Korea), Aji Bio-Pharma (Japan), Hzymes (China), KACTUS (China), Yinjia (China), Generaybiotech (China) | Cost leadership (20-40% below Western), domestic market, export |
| 2 | Specialists | Codexis (US, protein engineering), Almac (UK, diagnostic manufacturing) | Custom enzymes, GMP-grade |
Technology roadmap (2027-2030):
- RNA ligase with template-independent ligation – Ligation without complementary overhangs, simplifying synthetic biology workflows. Research stage.
- Thermostable RNA ligase for PCR-based workflows – Ligate at elevated temperatures (60-70°C), reducing secondary structure interference. NEB and Yeasen developing.
- Engineered ligases for non-canonical nucleotides – Ligating modified RNA (2′-O-methyl, locked nucleic acids) for therapeutic applications.
With 4.3% CAGR, the RNA ligase market benefits from NGS growth (small RNA-seq, single-cell RNA-seq), synthetic biology, and emerging RNA therapeutics. Risks include competition from T4 DNA ligase (for certain RNA applications), automation reducing enzyme consumption (microfluidic platforms use 10-100x less reagent), and price pressure from Asian suppliers (20-40% lower).
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
